The role of positron emission tomography scanning in patients with radioactive iodine scan-negative, recurrent differentiated thyroid cancer

American Surgeon

Volumn 73, Issue 10, 2007, Pages 1052-1056

  Roberts, Micah ^a   Maghami, Ellie ^a   Kandeel, Fouad ^a   Yamauchi, David ^a   Ellenhorn, Hannah Leeba ^a   Ellenhorn, Joshua D I ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; THYROGLOBULIN; THYROGLOBULIN ANTIBODY; DIAGNOSTIC AGENT; RADIOACTIVE IODINE;

ARTICLE; CANCER DIAGNOSIS; CANCER SCINTISCANNING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; HUMAN; IMAGING SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; RECURRENT CANCER; RETROSPECTIVE STUDY; SUBTOTAL THYROIDECTOMY; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; WHOLE BODY PET; WHOLE BODY SCINTISCANNING; BLOOD; CELL DIFFERENTIATION; PATHOLOGY; RECURRENT DISEASE; SCINTISCANNING; THYROID TUMOR; TUMOR RECURRENCE; WHOLE BODY IMAGING;

CELL DIFFERENTIATION; HUMANS; IODINE RADIOISOTOPES; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RECURRENCE; RETROSPECTIVE STUDIES; THYROGLOBULIN; THYROID NEOPLASMS; WHOLE BODY IMAGING;

EID: 38449094806     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Sherman SI, Angelos P, Ball DW, et al. Thyroid carcinoma. J Natl Compr Cane Netw 2005;3:404-57.
2. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109-42.
3. Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 1999;9:421-7.
4. Sherman SI, Angelos P, Ball DW, et al. Thyroid carcinoma. J Natl Compr Canc Netw 2005;3:404-57.
5. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109-42.
6. Black EG, Sheppard MC, Hoffenberg R. Serial serum thyroglobulin measurements in the management of differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 1987;27:115-20.
7. Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 1999;9:421-7.
8. Clark OH, Hoelting T. Management of patients with differentiated thyroid cancer who have positive serum thyroglobulin levels and negative radioiodine scans. Thyroid 1994;4:501-5.
9. Choi MY, Chung JK, Lee HY, et al. The clinical impact of 18F-FDG PET in papillary thyroid carcinoma with a negative 1311 whole body scan: A single-center study of 108 patients. Ann Nucl Med 2006;20:547-52.
10. Nahas Z, Goldenberg D, Fakhry C, et al. The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope 2005;115:237-43.
11. Laking GR, Price PM. Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. J Nucl Med 2002;43:1728-9.
12. Schluter B, Bohuslavizki KH, Beyer W, et al. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med 2001;42:71-6.
13. Sherman SI, Angelos P, Ball DW, et al. Thyroid carcinoma. J Natl Compr Cane Netw 2005;3:404-57.
14. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109-42.
15. Kloos RT, Mazzaferri EL. A single recombinant human thyrotropin- stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 2005;90:5047-57.
16. Sherman SI, Angelos P, Ball DW, et al. Thyroid carcinoma. J Natl Compr Cane Netw 2005;3:404-57.
17. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109-42.
18. Zimmer LA, McCook B, Meltzer C, et al. Combined positron emission tomography/computed tomography imaging of recurrent thyroid cancer. Otolaryngol Head Neck Surg 2003;128:178-84.
19. Frilling A, Tecklenborg K, Gorges R, et al. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg 2001;234:804-11.
20. Holt E. Controversies in the surveillance of patients with well differentiated thyroid cancer. Curr Opin Oncol 2007;19:6-10.
21. Choi MY, Chung JK, Lee HY, et al. The clinical impact of 18F-FDG PET in papillary thyroid carcinoma with a negative 1311 whole body scan: A single-center study of 108 patients. Ann Nucl Med 2006;20:547-52.
22. Grunwald F, Menzel C, Bender H, et al. Comparison of 18FDG-PET with 131iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 1997;7:327-35.
23. Frilling A, Tecklenborg K, Gorges R, et al. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg 2001;234:804-11.
24. Frilling A, Tecklenborg K, Gorges R, et al. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg 2001;234:804-11.
25. Chin BB, Patel P, Cohade C, et al. Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 2004;89:91-5.
26. Saab G, Driedger AA, Pavlosky W, et al. Thyroid-stimulating hormone-stimulated fused positron emission tomography/computed tomography in the evaluation of recurrence in 131I-negative papillary thyroid carcinoma. Thyroid 2006;16:267-72.
27. Palmedo H, Bucerius J, Joe A, et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 2006;47:616-24.
28. Robbins RJ, Wan Q, Grewal RK, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006;91:498-505.